Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -56M | -19M | -8M | -11M | -33M |
| EBITDA | -56M | -18M | -8M | -11M | -32M |
| Net Income | -53M | -18M | -8M | -11M | -32M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$12.00
+1.10% today
1Y Change
+111.21%
Window
Jun 23, 2025 → Jun 17, 2026
Coverage: 248 bars · Jun 23, 2025 → Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Tenax Therapeutics, Inc. (TENX) is a Healthcare stock with a market cap of $220.00M and listed on NASDAQ. The stock last traded around $12.00 and up 111.2% across the available one-year price window (Jun 23, 2025 → Jun 17, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -16.5%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -16.5%, free cash flow -141.7% with operating margin 0.0% and ROIC -58.1%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines TENX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TENX
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
TENX Max Drawdown
-42.31%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for TENX and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$32.5M
-193.9% YoY
Free Cash Flow
-$10.9M
+9.6% YoY
Revenue Growth
+0.0%
EPS Growth
-16.5%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -56M | -19M | -8M | -11M | -33M |
| EBITDA | -56M | -18M | -8M | -11M | -32M |
| Net Income | -53M | -18M | -8M | -11M | -32M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 98M | 95M | 10M | 2M | 6M |
| Total Assets | 104M | 97M | 12M | 3M | 6M |
| Total Liabilities | 7M | 5M | 4M | 2M | 2M |
| Shareholder Equity | 97M | 92M | 8M | 1M | 4M |
| Total Debt | 0 | 0 | 501K | 808K | 291K |
| Net Debt | -98M | -95M | -9M | -1M | -5M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
11M
+9.6% YoY
Capital Expenditures
5K
-125.7% YoY
Free Cash Flow
11M
+9.6% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-51.8%
Debt / Equity
0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.